Archive for category: News

Cardiovascular diseases (CVD) account for 24.8% of all deaths in India, with an age-standardized death rate of 272 per 100,000-higher than the global average. (1) Indians develop CVD nearly a decade earlier than Western populations, with 62% of deaths occurring prematurely. Key cardiometabolic risk factors-hypertension, diabetes, and obesity-have driven a 2.3-fold rise in ischemic heart disease and stroke. (2)

CVD complications are also evident in acute settings: 20% of adults hospitalized with pneumococcal pneumonia experience heart failure, arrhythmia, or myocardial infarction. (3) Nearly 12% of patients developed heart failure within a decade of hospitalization, highlighting the prolonged cardiovascular impact of systemic infections such as pneumonia. (4)

Cardiopulmonary Overlap and Risk of Respiratory Infections in CVD

Cardiovascular and respiratory diseases frequently coexist due to shared risk factors such as smoking and systemic inflammation.(5) Symptom overlap is common-cardiac conditions like heart failure may present with respiratory features (e.g., cardiac asthma), while chronic lung disease increases right ventricular strain, predisposing to CHF. (6)

The risk intensifies with respiratory infections. Patients with cardiovascular disease—including CHF, valvular disease, and congenital heart disease—face a 3.3-fold higher risk of community-acquired pneumonia (CAP) and a 9.9-fold higher risk of invasive pneumococcal disease (IPD). (7) During IPD, Streptococcus pneumoniae translocate across the vascular endothelium and invades the myocardium, directly killing cardiomyocytes and immune cells. (8) This results in acute myocardial injury and can lead to long-term cardiac dysfunction, compounding the cardiovascular burden in affected patients. (9)

Clinical trials such as PARADIGM-HF and PARAGON-HF have demonstrated a significant incidence of pneumonia among heart failure patients. Pneumonia occurred in 6.3% (29 per 1,000 patient-years) of PARADIGM-HF patients and 10.6% (39 per 1,000 patient-years) of PARAGON-HF participants. The onset of pneumonia in these patients substantially increased the risk of adverse outcomes. (10)

Importance of Preventing Pneumococcal Disease in Cardiovascular Disease Patients

Figure: Streptococcus pneumoniae induces cardiovascular complications via multiple pathophysiological mechanisms. Adapted from Restrepo MI, Reyes LF. Respirology. 2018;23(3):250-259.

Preventing pneumococcal disease is vital for CVD patients, particularly those with heart failure and CAD, as they are more vulnerable to bacterial infections like pneumonia and other respiratory illnesses. These infections can trigger cardiac decompensation, increasing hospitalizations and mortality. Vaccination against pneumococcus lowers the risk of respiratory infections, heart failure exacerbations, and cardiovascular events. Given weakened immunity and constant exposure to airborne pathogens, vaccination helps stabilize heart function, reduce inflammation, and ease healthcare burdens. (11)

Pneumococcal Vaccination in Cardiovascular Diseases – When to Consider?

Table 1 provides adult vaccine recommendations for heart failure and related high-risk conditions per the API(Association of Physicians of India) 2024 guidelines.

Table 1: Vaccination Recommendations for High-Risk Cardiac and Chronic Conditions

Vaccination should be considered a priority for individuals with CVD, as they are inherently immunocompromised due to circulatory impairment and elevated inflammatory cytokines. Advancing age (55+), diabetes, and hypertension further increase infection risk and worsen CAD. Those with congenital or valvular heart disease and post-cardiac surgery patients also face high infection risks and must adhere to vaccination protocols, particularly for pneumococcal vaccine. (12)

Pneumococcal conjugate vaccine (PCV13) should be administered first, followed by the pneumococcal polysaccharide vaccine (PPSV23) after eight weeks. (13)

Vaccination in Cardiovascular Diseases – View of Scientific Authorities

Table 2 lists vaccines with Class recommendations for adults with cardiovascular and related chronic conditions. (13)

Table 2: Approved Class I Vaccine Recommendations in High-Risk Adults

Leading health organizations strongly recommend pneumococcal and influenza vaccination for patients with chronic cardiovascular disease. The Centers for Disease Control and Prevention/Advisory Committee on Immunization Practices (CDC/ACIP) advises pneumococcal vaccination for all adults over 50 and high-risk cardiovascular patients, alongside annual influenza vaccination for those with chronic heart and lung diseases. (14) Table 3 summarizes key vaccination recommendations from major global and national health authorities. 

Table 3: Pneumococcal Vaccination Recommendations by Leading Health Organizations

Additional recommended vaccines include Hepatitis B, which supports liver and overall health, and the shingles (herpes zoster) vaccine, as heart failure patients are prone to outbreaks due to stress, viral infections, and immune dysfunction.(12)

Effectiveness of Pneumococcal Vaccination in Improving Cardiovascular Outcomes

Vaccination significantly reduces hospitalizations and cardiovascular complications. A meta-analysis of 15 studies (347,444 patients) showed that pneumococcal vaccination reduced all-cause mortality by 24% (HR: 0.76, 95% CI: 0.66–0.87, p< 0.001) and myocardial infarction (MI) by 27% (HR: 0.73, 95% CI: 0.56–0.96, p = 0.02). (17) Another meta-analysis of seven studies (163,756 participants) showed pneumococcal vaccination reduced all-cause mortality by 22% (HR: 0.78, 95% CI: 0.73–0.83, p < 0.001). These findings highlight pneumococcal vaccination as a crucial preventive strategy for individuals at high cardiovascular risk, particularly those aged ≥65 years. (18)

Overcoming Barriers to Vaccination in Cardiac Patients – Multi-stakeholder Approach

Vaccine adherence remains low due to concerns about side effects, physician hesitancy, and cost. While cost is a barrier, hospitalization expenses for preventable infections are far higher. To improve adherence, public health initiatives, patient education, and enhanced accessibility are key. Effective strategies include patient messaging and community education to emphasize vaccines as essential for reducing cardiovascular risk and improving long-term health. (19)

Take Home Message

• CVD causes 24.8% of all deaths in India, with earlier onset and high premature mortality-highlighting the need to reduce preventable complications and secondary risks.
• Patients with CVD face a 3.3-fold higher risk of pneumonia and a 9.9-fold higher risk of invasive pneumococcal disease, which can cause acute and long-term myocardial damage.
• Pneumococcal vaccination lowers all-cause mortality by up to 24% and reduces myocardial infarction risk by 27%, supporting its role in cardiovascular risk reduction.
• API recommends pneumococcal vaccination for adults aged 18–49 with comorbidities, including chronic heart disease, and for all adults aged above 50.
• Despite strong endorsements from CDC, AHA, ESC, and Indian consensus guidelines, vaccine uptake in cardiac patients remains low-necessitating targeted education and public health action.

References:

1. Jan, Bisma et al. “Cardiovascular Diseases Among Indian Older Adults: A Comprehensive Review.” Cardiovascular therapeutics vol. 2024 6894693. 25 Jun. 2024.

2. Kalra, Ankur et al. “The burgeoning cardiovascular disease epidemic in Indians – perspectives on contextual factors and potential solutions.” The Lancet regional health. Southeast Asia vol. 12 100156. 10 Feb. 2023, doi:10.1016/j.lansea.2023.100156

3. Musher, Daniel M et al. “The association between pneumococcal pneumonia and acute cardiac events.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 45,2 (2007): 158-65. doi:10.1086/518849

4. Eurich, Dean T et al. “Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up.” BMJ (Clinical research ed.) vol. 356 j413. 13 Feb. 2017, doi:10.1136/bmj.j413

5. Carter, Paul et al. “Association of Cardiovascular Disease With Respiratory Disease.” Journal of the American College of Cardiology vol. 73,17 (2019): 2166-2177. doi:10.1016/j.jacc.2018.11.063

6. Buckner, Kern. “Cardiac asthma.” Immunology and allergy clinics of North America vol. 33,1 (2013): 35-44. doi:10.1016/j.iac.2012.10.012

7. Torres, Antoni et al. “Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.” Thorax vol. 70,10 (2015): 984-9. doi:10.1136/thoraxjnl-2015-206780

8. Brown, Armand O et al. “Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function.” PLoS pathogens vol. 10,9 e1004383. 18 Sep. 2014, doi:10.1371/journal.ppat.1004383

9. Shenoy, Anukul T et al. “Streptococcus pneumoniae in the heart subvert the host response through biofilm-mediated resident macrophage killing.” PLoS pathogens vol. 13,8 e1006582. 25 Aug. 2017, doi:10.1371/journal.ppat.1006582

10. Shen L, Jhund PS, Anand IS, et al. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021;77(16):1961-1973.

11. Bhatt AS, DeVore AD, Hernandez AF, Mentz RJ. Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions. JACC Heart Fail. 2017;5(3):194-203.

12. Centers for Disease Control and Prevention. “Vaccination Information for Adults with Heart Disease.” CDC, https://www.cdc.gov/vaccines/adults/rec-vac/heart-disease-home.html. Accessed 19 Feb. 2025.

13. Indian Consensus Guideline on Adult Immunization.EMVAC, June 2024, https://www.emvac.in/wp-content/uploads/2024/06/Adult-Vaccination-Booklet.pdf. Accessed 25 Feb. 2025.

14. U.S. Centers for Disease Control and Prevention.CDC Recommends Lowering the Age for Pneumococcal Vaccination from 65 to 50 Years Old. Accessed on 2nd January 2025 from https://www.cdc.gov/media/releases/2024/s1023-pneumococcal-vaccination.html

15. Jaiswal V, Ang SP, Lnu K, et al. Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. J Clin Med. 2022;11(13):3799. Published 2022 Jun 30. doi:10.3390/jcm11133799

16. World Health Organization. (n.d.). Pneumonia. Immunization, Vaccines and Biologicals. Retrieved from https://www.who.int/

17. Jaiswal V, Ang SP, Lnu K, et al. Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. J Clin Med. 2022;11(13):3799. Published 2022 Jun 30.

18. Marques Antunes M, Duarte GS, Brito D, et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2021;7(1):97-106.

19. García-Zamora S, Pulido L. Vaccines in cardiology, an underutilized strategy to reduce the residual cardiovascular risk. Arch Peru Cardiol Cir Cardiovasc. 2024;5(1):29-39. Published 2024 Mar 19.

Visakhapatnam: The Andhra Pradesh High Court has dismissed a writ petition challenging the newly adopted method for
conducting gap analysis of Common Bio-Medical Waste Treatment and
Disposal Facilities (CBWTFs) in the state. The Court held that such matters fall
under the expertise of specialised bodies, and judicial interference should be
limited.

Also Read:Courts must exercise caution before interfering with Educational standards set by NMC: HC

Also Read:Bombay HC Notice to CDSCO on Denial of Phase I Trial for Indigenous Cancer Drug

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even before significant weight loss occurs and prior to reaching the full target dose.

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, according to a secondary analysis of the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial from the same international author team being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May).

“These results highlight semaglutide’s early action on decreasing major cardiovascular events, with significant benefits already evident by the first 6 months, and for some, even earlier, even before any major weight loss and before most patients would have been titrated to their full target dose of 2.4 mg,” said lead author Dr Jorge Plutzky, Director of Preventive Cardiology, Cardiovascular Medicine at Brigham and Women’s Hospital, Boston, MA, USA and a member of SELECT Steering Committee.

Semaglutide is a GLP-1 medication initially approved for treating adults with type 2 diabetes, in whom it has already shown cardiovascular benefit. But semaglutide is also approved for weight loss in people with obesity or overweight who have at least one other health issue.

This GLP-1 class of medications simulate the functions of the body’s natural incretin hormones, which help to lower blood sugar levels after a meal and provide a fullness signal to the brain, helping patients to lower daily calorie intake and promoting their weight loss.

In 2023, in a landmark finding, the SELECT trial showed that adults with overweight or obesity but without diabetes, who had previously experienced a heart attack, stroke and/or had peripheral artery disease, taking semaglutide had a 20% reduction in major adverse cardiac events such as heart attacks and strokes compared to those on placebo over the course of 3 years [1]. SELECT was not specifically a weight loss trial; patients received semaglutide or placebo in a blinded manner, but did not receive dietary or weight loss guidance.

This new analysis presented at ECO, focused on the difference in early cardiovascular events with semaglutide versus placebo from randomisation up to 12 months, with a focus on 3 and 6 months, to better understand the drug’s effects, time to cardiovascular benefit, as well as predictors that might help identify patients at risk for early cardiovascular events.

The researchers looked at data from 17,604 adults (aged 45 or older; 72% male) from 804 sites in 41 countries with overweight or obesity (BMI of 27 kg/m² or higher) who were enrolled and treated with weekly injections of semaglutide (at doses slowly titrated to 2.4 mg at week 16) or placebo.

The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58 respectively)

Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113 respectively)

Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly.

“Our findings reveal an early separation in the treatment effect of semaglutide that occurs even without a significant amount of weight lost and prior to full semaglutide titration,” said Dr Plutzky. “More research is needed to understand the mechanisms through which semaglutide produces these early clinical benefits, but they may include the drug’s positive effects on reducing inflammation, blood sugar, blood pressure, direct effects on the heart and blood vessels, early dietary changes, or an interaction among these or other responses.”

Despite these important findings, the authors note that SELECT is not a trial looking to prevent first cardiovascular events-all SELECT patients had a history of heart disease, placing them at high risk. It is worth noting, they say, given their cardiovascular history, that SELECT patients were already on other cardio-protective medications, for example to tackle cholesterol and blood pressure, meaning semaglutide had benefits on top of these other agents.

Reference:

Semaglutide may provide early protection against heart disease in high-risk patients-even before clinically meaningful weight loss and prior to the full target dose, European Association for the Study of Obesity, Meeting: European Congress on Obesity (ECO2025).